Skip to main content
Premium Trial:

Request an Annual Quote

Tempus, University Hospitals Partner on Personalized Cancer Care

NEW YORK (GenomeWeb) – Ohio's University Hospitals Seidman Cancer Center will collaborate on personalized oncology for ovarian and triple negative breast cancer patients with Tempus, a genomic analysis firm.

Under the collaboration, Chicago-based Tempus will provide genomic and transcriptomic sequencing and analysis to help physicians find actionable information and treatment opportunities for those patients. More broadly, the partners will work to make genomic data, analysis, and clinical decision support available to oncologists at UH Seidman Cancer Center.

Financial and other terms of the arrangement were not disclosed.

"As we work to modernize cancer care, we are proud to bring the Tempus operating system and analytics platform to UH Seidman Cancer Center, empowering its physicians to make data-driven decisions tailored to its patients," Tempus CEO Eric Lefkofsky said in a statement.

UH Seidman Cancer Center is part of the National Cancer Institute-designated comprehensive cancer center at Case Western Reserve University.

The deal is the latest in a string of collaborations with high-profile medical centers for Tempus. Since October, the firm has officially linked up with Rush University Medical Center, the University of Pennsylvania's Abramson Cancer Center, and, most recently, the Mayo Clinic.